Xcovery Announces First Cohort of Patients Dosed in a Phase 1/2 Clinical Trial of Vorolanib in Combination with Nivolumab for Treatment of Non-small Cell Lung Cancer or Thymic Carcinoma

Palm Beach Gardens, Fla., July 31, 2018 – Xcovery, a developer of targeted therapeutics for cancer, today announced that the first cohort of patients has been enrolled to the Phase 1/2 clinical trial evaluating the safety and efficacy of the combination of vorolanib (X-82) and nivolumab (Opdivo®) for the treatment of non-small cell lung cancer […]